Andere Kunden interessierten sich auch für
![Reprogramming Microbial Metabolic Pathways]( "Reprogramming Microbial Metabolic Pathways")
Reprogramming Microbial Metabolic Pathways110,99 €![A Quick Guide to Metabolic Disease Testing Interpretation]( "A Quick Guide to Metabolic Disease Testing Interpretation")
A Quick Guide to Metabolic Disease Testing Interpretation65,99 €![Studies on solid and submerged fermentative production of xylanases]( "Studies on solid and submerged fermentative production of xylanases")
Studies on solid and submerged fermentative production of xylanases46,99 €![Microbes in Food]( "Microbes in Food")
Microbes in Food44,99 €![Production of Itaconic Acid at Laboratory & Bench Scale]( "Production of Itaconic Acid at Laboratory & Bench Scale")
Production of Itaconic Acid at Laboratory & Bench Scale23,99 €![Production of Ethanol using Yeast Isolates on Cellulosic Substrates]( "Production of Ethanol using Yeast Isolates on Cellulosic Substrates")
Production of Ethanol using Yeast Isolates on Cellulosic Substrates44,99 €![Metabolic Syndrome Among The Obstetric Population]( "Metabolic Syndrome Among The Obstetric Population")
Metabolic Syndrome Among The Obstetric Population26,99 €
Recent years have seen an increasing interest in metabolic engineering of C. glutamicum for production of organic acids. Here, we report a new engineered strain capable of lysine production, which has 10-fold high lysine production capacity than the wild type strain. In this book we provided further insight into AK regulation and function and also provided valuable information for engineering L-lysine producing C. glutamicum strains. The data provided in this book show the importance of the deregulation of aspartate kinase and site directed mutagenesis for overproduction of L-lysine in C. glutamicum. The new engineered strain in this study promises to create new opportunities in bioprocess performance and over produce L-lysine for therapeutic and biomedical applications. The recombinant strain described here may provide a basis for future metabolic engineering to obtain a further increase in lysine production by C. glutamicum. The newly engineered C. glutamicum potentially servesas a food grade and biomedically applicable platform for the production of lysine.
Recent years have seen an increasing interest in metabolic engineering of C. glutamicum for production of organic acids. Here, we report a new engineered strain capable of lysine production, which has 10-fold high lysine production capacity than the wild type strain. In this book we provided further insight into AK regulation and function and also provided valuable information for engineering L-lysine producing C. glutamicum strains. The data provided in this book show the importance of the deregulation of aspartate kinase and site directed mutagenesis for overproduction of L-lysine in C. glutamicum. The new engineered strain in this study promises to create new opportunities in bioprocess performance and over produce L-lysine for therapeutic and biomedical applications. The recombinant strain described here may provide a basis for future metabolic engineering toobtain a further increase in lysine production by C. glutamicum. The newly engineered C. glutamicum potentially serves as a food grade and biomedically applicable platform for the production of lysine.
Recent years have seen an increasing interest in metabolic engineering of C. glutamicum for production of organic acids. Here, we report a new engineered strain capable of lysine production, which has 10-fold high lysine production capacity than the wild type strain. In this book we provided further insight into AK regulation and function and also provided valuable information for engineering L-lysine producing C. glutamicum strains. The data provided in this book show the importance of the deregulation of aspartate kinase and site directed mutagenesis for overproduction of L-lysine in C. glutamicum. The new engineered strain in this study promises to create new opportunities in bioprocess performance and over produce L-lysine for therapeutic and biomedical applications. The recombinant strain described here may provide a basis for future metabolic engineering toobtain a further increase in lysine production by C. glutamicum. The newly engineered C. glutamicum potentially serves as a food grade and biomedically applicable platform for the production of lysine.